Zobrazeno 51 - 60
of 83
pro vyhledávání: '"Fara, A."'
Autor:
Joseph H Garcia, Fara Dayani, Ankush Chandra, Soumya Sagar, Manish K. Aghi, Jonathan Rick, Saman Arfaie, Polly Chuntova, Darryl Lau, Cecilia L Dalle Ore, Garima Yagnik, Angel Ordaz, Alan Nguyen
INTRODUCTION: Glioblastoma is an aggressive cancer with a dismal median survival of under two years. Recent studies have shifted the paradigm of glioblastoma from a homogenous mass of tumor cells into a complex organ containing interacting elements.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a487e6064efaf9ecb941cea7062bfdc
https://europepmc.org/articles/PMC6217110/
https://europepmc.org/articles/PMC6217110/
Autor:
Matthew S. Davids, Fara Faye Regis, Mei Zheng, Michaela Gruber, Jing Sun, Lillian Werner, Laura Z. Rassenti, Jessica Wong, Angela N. Brooks, Anthony Letai, Lili Wang, Catherine J. Wu, Thomas J. Kipps, Michael P. Thomas, Robin Reed, Jing Deng, Matthew Meyerson, Ruben D. Carrasco, Michael Seiler, Ekaterina Kim, Elisa Ten Hacken, Shanye Yin, Jan A. Burger, Amy L. Gill, Pavan Bachireddy, Silvia Buonamici, Rebecca Valentin, Pete Smith, Emanuela M. Ghia, Donna Neuberg
Publikováno v:
JCI insight, vol 3, iss 19
The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1164f1863e109b871fd48181d528273
https://escholarship.org/uc/item/70g3v1fm
https://escholarship.org/uc/item/70g3v1fm
Autor:
Maria Vidal, Belinda Salinas, Barbara Adamo, Aleix Prat, Blanca Gonzalez-Farre, Tomás Pascual, Montserrat Muñoz, Esther Sanfeliu, Meritxell Mallafré, Reinaldo Moreno, Laia Paré, Olga Martínez-Sáez, D. Martinez, Fara Brasó-Maristany, Patricia Galván, Nuria Chic
Publikováno v:
Cancer Research. 81:PS18-11
Background: There is an increasing need in the clinic to biopsy metastatic disease in patients with advanced breast cancer (ABC). However, the microenvironment and tumor cell biology of breast cancer metastasis is largely unknown. Here, we report a m
Autor:
Fara Brasó-Maristany, Sonia Servitja, Joaquín Gavilá, Patricia Galván, Serafin Morales, Laia Paré, Cristina Saura, Juan M Ferrero-Cafiero, Laura García-Estévez, Patricia Villagrasa, Javier Salvador Bofill, D. Martinez, Jordi Canes, Rubén del Toro, Esteban Nogales, Nuria Chic, Josefina Cruz, Sonia Pernas, Vanesa Quiroga, Aleix Prat, Maria Bermejo
Publikováno v:
Cancer Research. 81:OT-03
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15-20% of breast cancers (BC). At the same time, HER2-low tumors (immunohistochemistry 1+ or 2+ with no gene amplification) comprise ~50% of all BC. DS-8201a is a
Autor:
James W. Dear, Juan J. Díaz-Mochón, Mario Antonio Fara, Hugh Ilyine, Francisco Javier López-Delgado, Mavys Tabraue-Chávez, Rosario M. Sánchez-Martín, Antonio Marín-Romero, Salvatore Pernagallo, Juan J. Guardia-Monteagudo
Publikováno v:
Talanta
Marín-Romero, A, Tabraue-Chávez, M, Dear, J W, Sánchez-Martín, R M, Ilyine, H, Guardia-Monteagudo, J J, Fara, M A, López-Delgado, F J, Díaz-Mochón, J J & Pernagallo, S 2020, ' Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the Luminex MAGPIX system ', Talanta, vol. 219, 121265 . https://doi.org/10.1016/j.talanta.2020.121265
Marín-Romero, A, Tabraue-Chávez, M, Dear, J W, Sánchez-Martín, R M, Ilyine, H, Guardia-Monteagudo, J J, Fara, M A, López-Delgado, F J, Díaz-Mochón, J J & Pernagallo, S 2020, ' Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the Luminex MAGPIX system ', Talanta, vol. 219, 121265 . https://doi.org/10.1016/j.talanta.2020.121265
Dynamic chemical labelling is a single-base specific method to enable detection and quantification of micro-Ribonucleic Acids in biological fluids without extraction and pre-amplification. In this study, dynamic chemical labelling was combined with t
Autor:
Andreu Prat, Olga Martínez-Sáez, T. Pascual, Blanca Gonzalez-Farre, A. Rodriguez Hernandez, Nuria Chic, Esther Sanfeliu, R. Moreno, Francesco Schettini, M. Vidal, B. Adamo, Benedetta Conte, Dianny Martínez, Iris Faull, E.M. Ciruelos, Aurelio Rodríguez, Fara Brasó-Maristany, Justin I. Odegaard, Montse Muñoz, Patricia Galván
Publikováno v:
Annals of Oncology. 31:S17
Autor:
Aranzazu Fernandez-Martinez, Giuseppe Perrone, Blanca Gonzalez-Farre, Benedetta Conte, Laia Paré, Esther Sanfeliu, J. Gavila Gregori, Andreu Prat, T. Pascual, Fara Brasó-Maristany, M. Martin Jimenez, B. Adamo, A. Lluch, Patricia Villagrasa, Francesco Schettini, S. De Placido, Olga Martínez-Sáez, Carlos H. Barrios, Nuria Chic, M.J. Mendez Vidal
Publikováno v:
Annals of Oncology. 31:S24
Autor:
Annette M. Molinaro, Ishan Kanungo, Mitchel S. Berger, Sarah Choi, Michael W. McDermott, Fara Dayani, Manish K. Aghi, Drew Weinstein, Patrick M. Flanigan, Arman Jahangiri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce87e78c675bb8509e18239e22bdcac
https://europepmc.org/articles/PMC5692722/
https://europepmc.org/articles/PMC5692722/
Publikováno v:
Indonesian Journal of Obstetrics and Gynecology (2015)
Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with histor
Autor:
Patricia Galván, Gaia Griguolo, Loredana Urso, Sara Balduzzi, Maria Vittoria Dieci, Antonino Musolino, Ornella Garrone, Valentina Guarneri, Roberto D'Amico, Luigi Cavanna, Giancarlo Bisagni, Alba A. Brandes, Fara Brasó Maristany, Aleix Prat, Anita Rimanti, Pierfranco Conte, Antonio Frassoldati, Enrico Orvieto, Francesco Giotta, Antonino Maiorana
Publikováno v:
Journal of Clinical Oncology. 37:544-544
544 Background: We investigated the prognostic role of the PAM50 HER2-enriched (HER2-E) subtype in HER2+ early breast cancer enrolled in the randomized Phase III ShortHER trial. Methods: The ShortHER study randomized 1254 HER2+ early breast cancer pa